Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LinkDoc Technology (Beijing) Co. Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The study was designed to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors
The trial is a multi-centre real-world non-interventional observational study to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors via a retrospectively review method on the study data on patient demographic/tumor biological characteristics and clinical treatments.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Surgeries and adjuvant therapies | Surgeries or surgeries plus adjuvant therapies |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surgeries | Procedure | Surgeries or surgeries plus adjuvant therapies |
|
| Measure | Description | Time Frame |
|---|---|---|
| Demographic characteristics of the patients with lung malignant tumors who received surgeries | Demographic characteristics of the patients with lung malignant tumors who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery as measured by:
| 2014 - 2017 |
| Measure | Description | Time Frame |
|---|---|---|
| Location of tumors and tumor sizes | Location of tumors and tumor sizes | 2014 - 2017 |
| Tumor clinical/pathological staging | Tumor clinical/pathological staging |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in overall survivals of the patients with surgeries | Differences in perioperative overall survivals and overall survivals of the patients who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery | 2014 - 2017 |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by tumor clinical/pathological staging |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with lung malignant tumors who were performed with surgeries
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lunxun Liu, PhD | West China Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China-Japan Friendship Hospital | Beijing | Beijing Municipality | 100029 | China | ||
| China PLA General Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 2014 - 2017 |
| Type of biomarkers | Type of biomarkers | 2014 - 2017 |
Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by tumor clinical/pathological staging |
| 2014 - 2017 |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by location of tumors and tumor sizes | Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by location of tumors and tumor sizes | 2014 - 2017 |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by duration and modes of surgeries | Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by duration and modes of surgeries | 2014 - 2017 |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by type of insurances | Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by type of insurances | 2014 - 2017 |
| Overall survival in the patients with tumor size =< 2cm who received surgeries | Overall survival in the patients with tumor size =< 2cm who received surgeries | 2014 - 2017 |
| Impact factors of patient survivals in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies | Impact factors of patient survivals in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies | 2014 - 2017 |
| Overall survival in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies | Overall survival in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies | 2014 - 2017 |
| Impact factors of patient survivals in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies | Impact factors of patient survivals in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies | 2014 - 2017 |
| Overall survival in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies | Overall survival in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies | 2014 - 2017 |
| Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies | Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies as measured by:
| 2014 - 2017 |
| Tumor clinical/pathological types | Tumor clinical/pathological types | 2014 - 2017 |
| Type of EGFR | Type of EGFR | 2014 - 2017 |
| ECOG scores | ECOG scores | 2014 - 2017 |
| 1-year and 3-year overall survivals | 1-year and 3-year overall survivals | 2014 - 2017 |
| Beijing |
| Beijing Municipality |
| 100853 |
| China |
| Henan cancer hospital | Zhengzhou | Henan | 450008 | China |
| Tongji Hospital Affiliated to Huaxi Technology University | Wuhan | Hubei | 430030 | China |
| Jiangsu cancer hospital | Nanjing | Jiangsu | 210009 | China |
| Xi'an Tangdu Hospital | Xi'an | Shaanxi | 710000 | China |
| Shanghai Chest Hospital | Shanghai | Shanghai Municipality | 200030 | China |
| West China Hospital, Sichuan University | Chengdu | Sichuan | 610041 | China |
| Tianjin Chest Hospital | Tianjin | Tianjin Municipality | 300051 | China |
| First Hospital Affiliated to Zhejiang University | Hangzhou | Zhejiang | 310003 | China |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |